|
|
Article: Abraxis BioScience Presents New Preclinical Data Demonstrating Eradication of Large Orthotopic Breast Tumors and Metastasis with Combined nab-Paclitaxel (ABRAXANE(R)) and Bevacizumab (Avastin(R)) Therapy.
- Article from:
- Business Wire
- Article date:
- April 15, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Findings Suggest ABRAXANE Avastin Combination Overcomes Newly Discovered Phenomenon of Reactionary Angiogenesis
Results Presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO -- Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biotechnology company, today presented preclinical data demonstrating the effect of ABRAXANE([R]) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with Avastin([R]) (bevacizumab) to eradicate large-sized (up to 600 mm3) orthotopic breast tumors and lymphatic and systematic metastasis at the American ...